Prosecution Insights
Prosecution Insights
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (75%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MELENDEZ, ARMAND | 1 | 46.2% | +42.8% |
| MCCORMICK, CATHERINE LYNN | 1 | 48.8% | +35.6% |
| TSAY, MARSHA M | 1 | 45.7% | +52.5% |
| HAVLIN, ROBERT H | 1 | 51.6% | +27.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17430557 | ANTIPRURITIC AGENT USING PAC1 RECEPTOR ANTAGONIST | HAVLIN, ROBERT H | 26d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17430557 | ANTIPRURITIC AGENT USING PAC1 RECEPTOR ANTAGONIST | HAVLIN, ROBERT H | 26d |
| 18569175 | CAPSULE PRODUCTION METHOD AND CAPSULE PRODUCTION DEVICE | MELENDEZ, ARMAND | — |
| 18548807 | HB-EGF GENE THERAPY FOR DIABETES | MCCORMICK, CATHERINE LYNN | — |
| 18253651 | LOW-DOSE HEPATOCYTE GROWTH FACTOR GENE THERAPY FOR DIABETES | TSAY, MARSHA M | — |
| Art Unit | Apps |
|---|---|
| 1759 | 1 |
| 1638 | 1 |
| 1656 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18569175 | CAPSULE PRODUCTION METHOD AND CAPSULE PRODUCTION DEVICE | MELENDEZ, ARMAND | 1759 | §103 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18548807 | HB-EGF GENE THERAPY FOR DIABETES | MCCORMICK, CATHERINE LYNN | 1638 | §103 | Final Rejection | — | Pending | Sep 01, 2023 |
| 18253651 | LOW-DOSE HEPATOCYTE GROWTH FACTOR GENE THERAPY FOR DIABETES | TSAY, MARSHA M | 1656 | §103 | Non-Final OA | — | Pending | May 19, 2023 |
| 17430557 | ANTIPRURITIC AGENT USING PAC1 RECEPTOR ANTAGONIST | HAVLIN, ROBERT H | 1626 | §103§112 | Non-Final OA | 26d | Pending | Jan 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial